Phathom Pharmaceuticals annual depreciation and amortization
2018
2019
2020
2021
2022
2023
2024
2025
Phathom Pharmaceuticals Depreciation & Amortization Growth & History (PHAT)
Phathom Pharmaceuticals's depreciation and amortization was $633,000 for fiscal 2025.
View full Phathom Pharmaceuticals company overviewPhathom Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $633,000 | −$162,000 | −20.38% |
| 2024 | 2024-12-31 | $795,000 | $220,000 | +38.26% |
| 2023 | 2023-12-31 | $575,000 | −$45,000 | −7.26% |
| 2022 | 2022-12-31 | $620,000 | $99,000 | +19.00% |
| 2021 | 2021-12-31 | $521,000 | $198,000 | +61.30% |
| 2020 | 2020-12-31 | $323,000 | $315,000 | +3937.50% |
| 2019 | 2019-12-31 | $8,000 | $8,000 | — |
| 2018 | 2018-12-31 | $0 | — | — |
Phathom Pharmaceuticals quarterly depreciation and amortization
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $114,000 | −$58,000 | −33.72% |
| Q1 2026 | 2026-03-31 | $110,000 | −$67,000 | −37.85% |
| Q4 2025 | 2025-12-31 | $128,000 | — | — |
| Q3 2025 | 2025-09-30 | $156,000 | −$44,000 | −22.00% |
| Q2 2025 | 2025-06-30 | $172,000 | −$28,000 | −14.00% |
| Q1 2025 | 2025-03-31 | $177,000 | −$37,000 | −17.29% |
| Q3 2024 | 2024-09-30 | $200,000 | $100,000 | +100.00% |
| Q2 2024 | 2024-06-30 | $200,000 | $100,000 | +100.00% |
| Q1 2024 | 2024-03-31 | $214,000 | $68,000 | +46.58% |
| Q3 2023 | 2023-09-30 | $100,000 | −$75,000 | −42.86% |
| Q2 2023 | 2023-06-30 | $100,000 | −$49,000 | −32.89% |
| Q1 2023 | 2023-03-31 | $146,000 | $18,000 | +14.06% |
| Q3 2022 | 2022-09-30 | $175,000 | $45,000 | +34.62% |
| Q2 2022 | 2022-06-30 | $149,000 | $18,000 | +13.74% |
| Q1 2022 | 2022-03-31 | $128,000 | $3,000 | +2.40% |
| Q3 2021 | 2021-09-30 | $130,000 | $42,000 | +47.73% |
| Q2 2021 | 2021-06-30 | $131,000 | $54,000 | +70.13% |
| Q1 2021 | 2021-03-31 | $125,000 | $73,000 | +140.38% |
| Q3 2020 | 2020-09-30 | $88,000 | $86,000 | +4300.00% |
| Q2 2020 | 2020-06-30 | $77,000 | $77,000 | — |
| Q1 2020 | 2020-03-31 | $52,000 | $52,000 | — |
| Q3 2019 | 2019-09-30 | $2,000 | — | — |
| Q2 2019 | 2019-06-30 | $0 | — | — |
| Q1 2019 | 2019-03-31 | $0 | — | — |
Phathom Pharmaceuticals depreciation and amortization trends
Over the last five fiscal years, Phathom Pharmaceuticals's depreciation and amortization increased from $323,000 to $633,000, a change of $310,000. The latest reported quarter, Q2 2026, shows $114,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Phathom Pharmaceuticals source filings ↗